Implanet SA (ALIMP) AI Stock Analysis

• Market Cap: €38.76M
• Dividend Yield: N/A
• Average Volume (3M): 534.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 52.11%
• EPS Growth: 68.65%
• Country: FR
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 143,543,900
• 10 Day Avg. Volume: 205,870
• 30 Day Avg. Volume: 534,862
• PEG Ratio: 0.04
• Price to Book (P/B): 18.30
• Price to Sales (P/S): 1.41
• P/FCF Ratio: -4.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: €0.50 ▲(92.31% Upside)

Implanet SA's overall stock score is primarily impacted by its weak financial performance and unattractive valuation. The technical analysis suggests a lack of strong momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors did not influence the score.

Implanet SA Business Overview & Revenue Model

Company Description

Implanet S.A., together with its subsidiaries, researches and develops, manufactures, and sells spinal and orthopedic implants. The company offers spinal and knee products. Its products include Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw systems for posterior fixation. The company also provides knee prostheses under the Madison name. Implanet S.A. has a strategic partnership with Shanghai Sanyou Medical Co, Ltd. The company was founded in 2006 and is based in Martillac, France.

How the Company Makes Money

Implanet SA generates revenue through the sale of its orthopedic implants, primarily targeting hospitals, clinics, and surgical centers. The company's key revenue streams include the JAZZ™ line of spinal implants, which are designed to improve the treatment of spinal conditions, and the MADISON™ knee implant, used in knee arthroplasty procedures. Additionally, Implanet collaborates with healthcare professionals and institutions to support product adoption and expand its market reach. Strategic partnerships and distribution agreements play a significant role in broadening its customer base and driving sales growth.

Implanet SA Financial Statement Overview

Summary

Implanet SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While recent revenue growth is promising, profitability remains elusive. The high leverage and negative equity expose the company to financial risks, necessitating strategic improvements in cost management and operational efficiency.

Income Statement

Implanet SA shows a fluctuating revenue trend with a recent uptick from 2023 to 2024. However, the company consistently reports negative EBIT and net income, indicating operational challenges and a lack of profitability. Gross profit margin has improved, but negative net profit and EBIT margins highlight ongoing struggles with cost management and profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio due to substantial debt levels and low stockholders' equity, which was negative in 2023. The equity ratio is minimal, indicating financial instability. The company’s assets are heavily leveraged, which may pose risks if revenue growth does not sustain.

Cash Flow

Cash flow analysis indicates persistent negative operating and free cash flows, revealing liquidity issues. Free cash flow growth was negative, and the operating cash flow to net income ratio reflects operational inefficiencies. Financing activities are crucial for liquidity, but reliance on external funding may not be sustainable long-term.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.41M	7.45M	8.03M	6.14M	3.89M
Gross Profit	4.10M	3.13M	3.91M	2.74M	1.59M
EBITDA	-3.82M	-5.08M	-2.46M	-3.26M	-1.46M
Net Income	-4.37M	-6.68M	-3.54M	-4.61M	-3.98M
Balance Sheet
Total Assets	14.89M	10.64M	14.47M	16.70M	8.70M
Cash, Cash Equivalents and Short-Term Investments	1.60M	248.00K	531.00K	1.87M	1.14M
Total Debt	6.17M	6.15M	6.80M	9.61M	4.66M
Total Liabilities	14.16M	10.81M	10.93M	13.90M	7.68M
Stockholders Equity	727.00K	-174.00K	3.54M	2.80M	1.02M
Cash Flow
Free Cash Flow	-2.81M	-2.17M	-3.04M	-3.91M	-3.29M
Operating Cash Flow	-2.32M	-1.45M	-2.47M	-3.52M	-3.07M
Investing Cash Flow	-844.00K	-768.00K	-570.00K	1.57M	-53.00K
Financing Cash Flow	4.37M	1.95M	1.60M	2.73M	3.77M

Implanet SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Neutral. The current price of 0.26 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.29, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 29.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALIMP.

Implanet SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALIMP	―	€38.76M	―	-450.14%	―	52.11%	68.65%
ALMDT	―	€113.04M	―	―	―	6.75%	15.48%
ALTHE	―	€27.75M	―	―	―	-54.44%	-51.95%